STAR Trial with Ji-Hong Liu

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Ji-Hong Liu to discuss the STAR Trial. Dr. Liu is a Professor in the Department of Gynecologic Oncology at Sun Yat-sen University Cancer Center. He is also President-elect of the Gynecologic Oncology Committee of China Anti-Cancer Association. Highlights: - In post-surgery treatment setting, adjuvant sequential chemoradiation was associated with improved disease-free survival compared with radiation alone or concurrent chemoradiation, and was well tolerated. - Sequential chemoradiation also decreased the risk of death compared with radiation alone. - Neither disease-free survival nor cancer death risk was different between patients treated with concurrent chemoradiation or radiation alone. - The detailed QOL results in comparisons between three arms will be orally presented at the annual meeting of SGO 2021 in March. - In conclusion, sequential chemoradiation (SCRT) after radical surgery resulted in a better disease-free survival and lower risk of cancer death for cervical cancer patients with adverse pathological factor, and could be an optimal adjuvant treatment in this setting.